Patents by Inventor William K. McVicar

William K. McVicar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9718853
    Abstract: The present invention provides novel anhydrous polymorph forms of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)]methyl nitrate (compound A), a selective adenosine A1 receptor agonist with a number of therapeutic uses including the treatment of elevated intra-ocular pressure. Also provided are methods for the preparation of the anhydrous polymorphic forms of compound A, pharmaceutical compositions and methods of treatment.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: August 1, 2017
    Assignee: Inotek Pharmaceuticals Corporation
    Inventor: William K. McVicar
  • Publication number: 20170151273
    Abstract: The present invention relates to an ophthalmic formulation which comprises a fine particle of Compound A in an aqueous suspension and a manufacturing process thereof. More specifically, the present invention relates to a topically applied ophthalmic aqueous suspension which is obtainable by suspending fine particles of Compound A in an aqueous vehicle containing a surfactant and boric acid. The invention also provides processes for making the ophthalmic formulations and to methods of use thereof.
    Type: Application
    Filed: November 8, 2016
    Publication date: June 1, 2017
    Inventors: William K. MCVICAR, Harun TAKRURI
  • Publication number: 20170049799
    Abstract: The present invention relates to an ophthalmic formulation which comprises a fine particle of Compound A in an aqueous suspension and a manufacturing process thereof. More specifically, the present invention relates to a topically applied ophthalmic aqueous suspension which is obtainable by suspending fine particles of Compound A in an aqueous vehicle containing a surfactant and boric acid. The invention also provides processes for making the ophthalmic formulations and to methods of use thereof.
    Type: Application
    Filed: November 8, 2016
    Publication date: February 23, 2017
    Inventors: William K. MCVICAR, Harun TAKRURI
  • Publication number: 20160367586
    Abstract: The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. The invention is particularly directed to a combination of latanoprost marketed under the brand Xalatan™ and Compound A.
    Type: Application
    Filed: May 18, 2016
    Publication date: December 22, 2016
    Inventors: Norman N. KIM, William K. MCVICAR, Thomas G. MCCAULEY, Rudolf A. BAUMGARTNER
  • Patent number: 9522160
    Abstract: The present invention relates to an ophthalmic formulation which comprises a fine particle of Compound A in an aqueous suspension and a manufacturing process thereof. More specifically, the present invention relates to a topically applied ophthalmic aqueous suspension which is obtainable by suspending fine particles of Compound A in an aqueous vehicle containing a surfactant and boric acid. The invention also provides processes for making the ophthalmic formulations and to methods of use thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 20, 2016
    Assignee: Inotek Pharmaceuticals Corporation
    Inventors: William K. McVicar, Harun Takruri
  • Patent number: 9499476
    Abstract: The compound of formula (I) is a water-stable, long acting ?2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like. Processes for making the compound of formula (I), as well as related intermediates, are disclosed.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: November 22, 2016
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Craig R. Abolin, H. Scott Wilkinson, Paul McGlynn, William K. McVicar
  • Patent number: 9370530
    Abstract: The present invention is directed to a composition or a kit comprising a combination of a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: June 21, 2016
    Assignee: Inotek Pharmaceuticals Corporation
    Inventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley, Rudolf A. Baumgartner
  • Publication number: 20160158268
    Abstract: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).
    Type: Application
    Filed: February 16, 2016
    Publication date: June 9, 2016
    Inventors: Norman N. KIM, William K. MCVICAR, Thomas G. MCCAULEY, Prakash JAGTAP
  • Publication number: 20160158267
    Abstract: The present invention is directed to selective adenosine A1 agonist compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, reduce or prevent age-related macular degeneration.
    Type: Application
    Filed: December 2, 2015
    Publication date: June 9, 2016
    Inventor: William K. MCVICAR
  • Publication number: 20160137686
    Abstract: The present invention provides novel anhydrous polymorph forms of 2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate (Compound A). The present invention also provides processes for preparation of the anhydrous polymorphic forms of compound A.
    Type: Application
    Filed: January 25, 2016
    Publication date: May 19, 2016
    Inventor: WILLIAM K. MCVICAR
  • Patent number: 9289383
    Abstract: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: March 22, 2016
    Assignee: Inotek Pharmaceuticals Corporation
    Inventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley, Prakash Jagtap
  • Patent number: 9278991
    Abstract: The present invention provides novel anhydrous polymorph forms of 2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) methyl nitrate (Compound A), a selective adenosine A1 receptor agonist with a number of therapeutic uses including the treatment of elevated intra-ocular pressure. Also provided are methods for the preparation of the anhydrous polymorphic forms of compound A, pharmaceutical compositions and methods of treatment.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: March 8, 2016
    Assignee: Inotek Pharmaceuticals Corporation
    Inventor: William K. McVicar
  • Publication number: 20150225334
    Abstract: The compound of formula (I) is a water-stable, long acting ?2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like. Processes for making the compound of formula (I), as well as related intermediates, are disclosed.
    Type: Application
    Filed: April 22, 2015
    Publication date: August 13, 2015
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Craig R. ABOLIN, H. Scott WILKINSON, Paul MCGLYNN, William K. MCVICAR
  • Patent number: 9040588
    Abstract: The compound of formula (I) is a water-stable, long acting ?2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like. Processes for making the compound of formula (I), as well as related intermediates, are disclosed.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: May 26, 2015
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Craig R. Abolin, H. Scott Wilkinson, Paul McGlynn, William K. McVicar
  • Publication number: 20150080330
    Abstract: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).
    Type: Application
    Filed: November 24, 2014
    Publication date: March 19, 2015
    Inventors: Norman N. KIM, William K. MCVICAR, Thomas G. MCCAULEY, Prakash JAGTAP
  • Publication number: 20150038448
    Abstract: The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. The invention is particularly directed to a combination of latanoprost marketed under the brand Xalatan™ and Compound A.
    Type: Application
    Filed: October 17, 2014
    Publication date: February 5, 2015
    Inventors: Norman N. KIM, William K. MCVICAR, Thomas G. MCCAULEY, Rudolf A. BAUMGARTNER
  • Patent number: 8895530
    Abstract: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: November 25, 2014
    Assignee: Inotek Pharmaceuticals Corporation
    Inventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley, Prakash Jagtap
  • Patent number: 8877732
    Abstract: The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: November 4, 2014
    Assignee: Inotek Pharmaceuticals Corporation
    Inventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley, Rudolf A. Baumgartner
  • Publication number: 20140271876
    Abstract: The present invention relates to an ophthalmic formulation which comprises a fine particle of Compound A in an aqueous suspension and a manufacturing process thereof. More specifically, the present invention relates to a topically applied ophthalmic aqueous suspension which is obtainable by suspending fine particles of Compound A in an aqueous vehicle containing a surfactant and boric acid. The invention also provides processes for making the ophthalmic formulations and to methods of use thereof.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: INOTEK PHARMACEUTICALS CORPORATION
    Inventors: William K. MCVICAR, Harun TAKRURI
  • Publication number: 20140275128
    Abstract: Provided herein are compounds of Formula I, compositions comprising an effective amount of a compound of Formula I, and methods for preventing, reducing or treating retinal ganglion cell damage comprising administering an effective amount of a purine derivative to a subject in need thereof.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: INOTEK PHARMACEUTICALS CORPORATION
    Inventor: William K. MCVICAR